Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 3-DIMENSIONAL PHARMACEUTICALS (DDDP) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (76)	5/31/2002 1:17:42 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 146

Didn't find anything useful in the 10-K...... Our hdm2 antagonist program, targeting a key molecular regulator of the well-known tumor suppressor gene p53, is also an area of active research in the pharmaceutical industry. In this regard, we are aware of pre-clinical research programs targeting hdm2 at AstraZeneca and Novartis AG. In additional, many companies are working on alternative ways to modulate normal p53 functioning, including various gene therapy and biological approaches.